NCT04616456 - Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 30, 2020

Primary Completion Date

January 30, 2022

Study Completion Date

January 30, 2022

Conditions

Multiple System AtrophyMultiple System Atrophy, Cerebellar VariantMultiple System Atrophy, Parkinson Variant (Disorder)Multiple System Atrophy (MSA) With Orthostatic Hypotension

Interventions

DRUG

[F-18]PBR06

PET radiopharmaceutical

DRUG

Verdiperstat

verdiperstat targets microglial inflammation in the brain

Trial Locations (1)

02115

Movement Disorders Clinic, 60 Fenwood Road, Boston